LONDON (Alliance News) - Scancell Holdings PLC Tuesday reported further encouraging results from its on-going phase I/2 clinical trial of its melanoma treatment SCIB1, as part of new data it presented at the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago.
The data showed that all sixteen patients with resected disease, meaning it has been cut out, are still alive. Survival times are "very encouraging", Scancell said.
Only give patients have had a recurrence of the disease, with all other patients disease free for between 27 and 46 months since they entered the study.
"The on-going positive results from this Phase 1/2 trial gives us confidence that our SCIB1 ImmunoBody has the potential to become the first non-toxic effective adjuvant treatment for resected melanoma," said Joint Chief Executive Officer Lindy Durrant in a statement.
"Data to date demonstrates that SCIB1 is safe and well-tolerated, and the very encouraging survival times suggest a strategy of using SCIB1 in such resected melanoma patients to extend their lives," Durrant added.
Shares in Scancell are trading down 5.8% at 36.02 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)